MA38112B1 - Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa - Google Patents

Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa

Info

Publication number
MA38112B1
MA38112B1 MA38112A MA38112A MA38112B1 MA 38112 B1 MA38112 B1 MA 38112B1 MA 38112 A MA38112 A MA 38112A MA 38112 A MA38112 A MA 38112A MA 38112 B1 MA38112 B1 MA 38112B1
Authority
MA
Morocco
Prior art keywords
modulators
gabaa receptor
derivatives
imidazopyridazine derivatives
relates
Prior art date
Application number
MA38112A
Other languages
English (en)
Other versions
MA38112A1 (fr
Inventor
Kiyoyuki Omoto
Robert Mckenzie Owen
David Cameron Pryde
Christine Anne Louise Watson
Mifune Takeuchi
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA38112A1 publication Critical patent/MA38112A1/fr
Publication of MA38112B1 publication Critical patent/MA38112B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention se rapporte au domaine des composés chimiques et concerne des dérivés d'imidazopyridazine. Plus particulièrement, l'invention concerne des dérivés de 4-(biphényl-3-yl)-7h-imidazo[4,5-c]pyridazine de formule (i) et les sels pharmaceutiquement acceptables de ceux-ci, où r
MA38112A 2012-12-14 2013-12-04 Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa MA38112B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737157P 2012-12-14 2012-12-14
PCT/IB2013/060631 WO2014091368A1 (fr) 2012-12-14 2013-12-04 Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa

Publications (2)

Publication Number Publication Date
MA38112A1 MA38112A1 (fr) 2018-03-30
MA38112B1 true MA38112B1 (fr) 2018-10-31

Family

ID=49880883

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38112A MA38112B1 (fr) 2012-12-14 2013-12-04 Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa

Country Status (43)

Country Link
US (3) US8952008B2 (fr)
EP (1) EP2938615B1 (fr)
JP (1) JP5869740B2 (fr)
KR (1) KR101746314B1 (fr)
CN (1) CN104837843B (fr)
AP (1) AP2015008526A0 (fr)
AR (1) AR093937A1 (fr)
AU (1) AU2013356894B2 (fr)
BR (1) BR112015014097B1 (fr)
CA (1) CA2892174C (fr)
CL (1) CL2015001652A1 (fr)
CR (1) CR20150254A (fr)
CU (1) CU24338B1 (fr)
CY (1) CY1118568T1 (fr)
DK (1) DK2938615T3 (fr)
DO (1) DOP2015000147A (fr)
EA (1) EA025635B1 (fr)
EC (1) ECSP15029822A (fr)
ES (1) ES2608640T3 (fr)
GE (1) GEP201706710B (fr)
GT (1) GT201500159A (fr)
HR (1) HRP20161559T1 (fr)
HU (1) HUE032400T2 (fr)
IL (1) IL239243A0 (fr)
LT (1) LT2938615T (fr)
MA (1) MA38112B1 (fr)
MD (1) MD4651B1 (fr)
ME (1) ME02566B (fr)
MX (1) MX366023B (fr)
NI (1) NI201500081A (fr)
PE (1) PE20151163A1 (fr)
PH (1) PH12015501293A1 (fr)
PL (1) PL2938615T3 (fr)
PT (1) PT2938615T (fr)
RS (1) RS55307B1 (fr)
SG (1) SG11201503735YA (fr)
SI (1) SI2938615T1 (fr)
TN (1) TN2015000261A1 (fr)
TW (1) TWI478926B (fr)
UA (1) UA112028C2 (fr)
UY (1) UY35185A (fr)
WO (1) WO2014091368A1 (fr)
ZA (1) ZA201504226B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3154979B1 (fr) * 2014-06-12 2018-03-07 Pfizer Limited Dérivés d'imidazopyridazine utilisés comme modulateurs de l'activité des récepteurs gabaa.
JP6625610B2 (ja) 2014-07-31 2019-12-25 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ピラゾールの調製方法
CN107592859A (zh) 2015-05-11 2018-01-16 巴斯夫欧洲公司 制备4‑氨基哒嗪类的方法
WO2017098367A1 (fr) 2015-12-10 2017-06-15 Pfizer Limited Dérivés 4-(biphényl-3-yl)-1h-pyrazolo[3,4-c]pyridazine de formule (i) utilisés comme modulateurs de récepteur gaba pour le traitement de l'épilepsie et de la douleur
WO2018055550A1 (fr) * 2016-09-23 2018-03-29 Novartis Ag Composés d'indazole destinés à être utilisés dans des lésions de tendon et/ou de ligament
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2018082964A1 (fr) 2016-11-04 2018-05-11 Basf Se Procédé de production de pyridazinyle-amides dans une synthèse one pot
BR112019022837A2 (pt) 2017-05-02 2020-05-26 Bayer Aktiengesellschaft Derivados heterocíclicos bicíclicos condensados substituídos por 2-(het)arila como agentes de controle de praga
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
WO2019226820A1 (fr) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Composés modulateurs allostériques positifs gabaa pour le traitement du prurit et/ou de la dermatite
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
CN116693555B (zh) 2022-02-25 2025-07-04 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN117069725A (zh) * 2022-05-10 2023-11-17 上海赛默罗生物科技有限公司 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途
AU2024262043A1 (en) 2023-04-24 2025-11-20 Shanghai SIMR Biotechnology Co., Ltd Imidazopyridine or imidazopyrazine compound, preparation method therefor, and pharmaceutical composition and use thereof
CN116655475B (zh) * 2023-05-19 2024-12-31 山东轩鸿生物医药有限公司 一种盐酸氟西汀的制备方法
WO2025137437A1 (fr) 2023-12-21 2025-06-26 Pfizer Inc. Formes solides d'un modulateur du récepteur gabaa et leurs procédés d'utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
AU1253002A (en) 2000-11-10 2002-05-21 Merck Sharp & Dohme Imidazo-triazine derivatives as ligands for gaba receptors
CA2555263A1 (fr) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines et ligands associes des recepteurs de benzodiazepine
WO2006078891A2 (fr) 2005-01-21 2006-07-27 Neurogen Corporation Derives heteroaryles d'imidazolylmethyle et de pyrazolylmethyle
EP1845098A1 (fr) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, leur procédés de préparation et leur utilisation comme ligands du recepteur GABA
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
CA2747419C (fr) 2009-01-12 2014-07-08 Icagen, Inc. Derives sulfonamides
PH12012500778A1 (en) * 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
ES2526675T3 (es) * 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje

Also Published As

Publication number Publication date
EP2938615A1 (fr) 2015-11-04
CR20150254A (es) 2015-07-09
HUE032400T2 (hu) 2017-09-28
TN2015000261A1 (fr) 2016-10-03
CA2892174A1 (fr) 2014-06-19
TW201434840A (zh) 2014-09-16
SI2938615T1 (sl) 2017-02-28
DK2938615T3 (da) 2017-01-02
RS55307B1 (sr) 2017-03-31
PT2938615T (pt) 2016-12-26
EA201590761A1 (ru) 2015-12-30
ME02566B (fr) 2017-02-20
CL2015001652A1 (es) 2015-08-14
IL239243A0 (en) 2015-07-30
UA112028C2 (uk) 2016-07-11
KR20150088877A (ko) 2015-08-03
PL2938615T3 (pl) 2017-04-28
SG11201503735YA (en) 2015-07-30
CU24338B1 (es) 2018-04-03
CN104837843A (zh) 2015-08-12
KR101746314B1 (ko) 2017-06-12
PE20151163A1 (es) 2015-08-14
CN104837843B (zh) 2016-08-31
AU2013356894A1 (en) 2015-05-28
PH12015501293B1 (en) 2015-08-24
AU2013356894B2 (en) 2015-11-12
MA38112A1 (fr) 2018-03-30
US20140171435A1 (en) 2014-06-19
JP5869740B2 (ja) 2016-02-24
CA2892174C (fr) 2018-02-06
PH12015501293A1 (en) 2015-08-24
MD20150051A2 (ro) 2015-09-30
UY35185A (es) 2014-07-31
MX2015007598A (es) 2015-10-22
DOP2015000147A (es) 2015-09-15
HRP20161559T1 (hr) 2016-12-30
ES2608640T3 (es) 2017-04-12
JP2016503001A (ja) 2016-02-01
EA025635B1 (ru) 2017-01-30
US20150105396A1 (en) 2015-04-16
US8952008B2 (en) 2015-02-10
HK1209743A1 (zh) 2016-04-08
MX366023B (es) 2019-06-24
LT2938615T (lt) 2016-12-27
US20150259352A1 (en) 2015-09-17
MD4651B1 (ro) 2019-09-30
GEP201706710B (en) 2017-07-25
AR093937A1 (es) 2015-07-01
EP2938615B1 (fr) 2016-10-26
NI201500081A (es) 2015-09-16
ECSP15029822A (es) 2017-08-31
CU20150058A7 (es) 2015-11-27
ZA201504226B (en) 2016-06-29
CY1118568T1 (el) 2017-07-12
TWI478926B (zh) 2015-04-01
WO2014091368A1 (fr) 2014-06-19
AP2015008526A0 (en) 2015-06-30
GT201500159A (es) 2015-09-23
BR112015014097B1 (pt) 2022-11-29
BR112015014097A2 (pt) 2019-12-17

Similar Documents

Publication Publication Date Title
MA38112A1 (fr) Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
MA37940A2 (fr) Nouveaux dérivés bicycliques
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
MA34078B1 (fr) Derives d'arylethynyle
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA35357B1 (fr) Composes de type anilines
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
TN2011000654A1 (fr) Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
MA35024B1 (fr) Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
EA201590979A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
EA201491002A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
MA38559B1 (fr) Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10
MA37618A1 (fr) Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx